ION Analytics Community

An error occurred trying to play the stream. Please reload the page and try again.

New to ION Analytics Events? Fill out the form below to create your FREE community account and select your ticket in step two.

Registered for an event before? Click "Already got an account" above to select your ticket in step two.

First Name

Last Name

Email

Job Title

Company

Phone

Please select an option

Key goals in my role are to (select multiple) Please select at least one option

By providing your information, you will also receive emails from ION Analytics regarding our business, products and services. You can update your preferences at any time. You can also view our Privacy Policy for full details.

First Name

Last Name

Email

Job Title

Company

Phone

Please select an option

Key goals in my role are to (select multiple) Please select at least one option

By providing your information, you will also receive emails from ION Analytics regarding our business, products and services. You can update your preferences at any time. You can also view our Privacy Policy for full details.

ECM Pulse

No market for small deals: ECM bankers eye mega listings to prize open Europe’s IPO window in 2024

Hold the fat lady: Tight AIB sell-down shows chances abound for blocks amid elusive IPO pipeline

Bad rates: CAB Payments "disaster" erases little faith left in IPOs 30 Oct 2023

A good deal in a bad market: CVC waits on IPO decision as Mid-East tensions rise and Vix spikes

Primary pick-me-up: companies plan equity financing as maturity wall approaches

Left for Fed: Renk’s pulled IPO sours mood as issuers mull Fed consequences

Simply the Best: IPO investors toast to Schott Pharma and turn eyes to CVC as next “must-have”

Mixed messages: IPO markets open, but cautious, following Arm’s share price fall

The spoils of war: Renk IPO to test appetite for defence stocks in the shadow of Ukraine

A Schott in the Arm – First big autumn IPOs excite but could still reopen old valuation wounds

Back in block: Accelerated bookbuilds to lead autumn issuance as investors seek performance differentiators

Not good enough: Bankers optimistic ahead of September but most IPO sellers will wait

Hydrocharged: Nucera just the start of Europe’s hydrogen IPO wave

The best defence: Investors turn to European defence stocks as Ukraine conflict lingers

Off the mark: Nucera breaks trading duck and shows path for green IPOs